Buenos Aires, Argentina (UroToday.com) Juan Pablo Sade, Institute Alexander Fleming, Argentina, discussed risk stratification and selection of which patients should undergo neoadjuvant chemotherapy (NAC).
Aside from clinical predictors we have subtypes basal and luminal to predict which patients may benefit from NAC vs. upfront radical cystectomy. P-53 like tend to be refractory to chemotherapy whereas basal have clear sensitivity and luminal is somewhat sensitive to chemotherapy. Further research and clinical incorporation into the precision management of these patients are needed. Once again costs should be reduced in order to allow feasibility to incorporate precision medicine into everyday practice and optimize the survival and reduce morbidity of this disease.
World Urological Oncology Federation Symposium at the SIU Congress 2016 - October 20 - 23, 2016 – Buenos Aires, Argentina
Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.